Healthcare >> CEO Interviews >> September 8, 2014
Paul A. Wagner is the Chief Financial Officer for Pfenex Inc. (NYSEMKT:PFNX). Dr. Wagner helped lead the company’s IPO; the partnership of Pfenex’s Lucentis biosimilar candidate with Hospira, a subsidiary of Pfizer; and its secondary equity offering. Dr. Wagner also serves on the executive steering committee, or ESC, for the Pfizer collaboration. Prior to joining the company, Dr. Wagner oversaw the U.S. biotechnology and pharmaceutical investments for Allianz Global Investors, where he worked from 2006 to 2014. Prior to that, Dr. Wagner was the Head of Development Licensing at PDL BioPharma, and prior to PDL BioPharma, Dr. Wagner was on the sell side, covering the biotechnology sector at the investment-banking firm Lehman Brothers. Dr. Wagner received a B.S. from the University of Wisconsin and a Ph.D. from the California Institute of Technology. He is also a CFA charterholder. Profile
Dr. Wagner: Pfenex is a biosimilar company that was spun out of The Dow Chemical Company in 2009 based on
